Tools

LEADER 02003nam 2200433 a 4500

001 ocm38371436;

003 OCoLC;

005 20160802102652.0;

007 he bmb024bbca;

008 980209s1996 dcua bb f000 0 eng d;

035 a| (Sirsi) o38371436;

035 a| (OCoLC)38371436;

043 a| n-us---;

049 a| ERE$;

074 a| 0546-D-01 (MF);

086 0 a| GA 1.5/2:T-PEMD-96-9;

100 1 a| Hamilton, Mary R.?| UNAUTHORIZED;

245 10 a| FDA review times :b| statement of Mary R. Hamilton, Director of Program Evaluation in Human Services Areas, Program Evaluation and Methodology Division, before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives /c| United States General Accounting Office.;

300 a| 13 pages, 2 unnumbered pages :b| illustrations ;c| 28 cm.;

336 a| text2| rdacontent;

337 a| microform2| rdamedia;

338 a| microfiche2| rdacarrier;

490 1 a| Testimony ;v| GAO/T-PEMD-96-9;

500 a| Distributed to depository libraries in microfiche.;

500 a| Shipping list no.: 98-0141-M.;

500 a| "May 2, 1996.";

504 a| Includes bibliographical references.;

610 10 a| United States.b| Food and Drug Administration.=| ^A1253;

650 0 a| Drugsz| United Statesx| Testing.=| ^A1001107;

650 0 a| Drugsx| Law and legislationz| United States.=| ^A639;

710 1 a| United States.b| General Accounting Office.=| ^A1924;

830 0 a| Testimonyv| GAO/T-PEMD-96-9.=| ^A682308;

949 a| GA 1.5/2:T-PEMD-96-9w| sudoch| joyner32o| jjlm;

596 a| 1;

998 a| 4469045;

999 a| GA 1.5/2:T-PEMD-96-9w| SUDOCc| 1i| 4469045-1001l| JDOMIm| JOYNERr| Ys| Yt| JDOFMIu| 7/14/2016x| MICROFORMz| JFEDDOCSo| .STAFF. jjlm;

FDA review times : statement of Mary R. Hamilton, Director of Program Evaluation in Human Services Areas, Program Evaluation and Methodology Division, before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives / United States General Accounting Office.

Author/creator	Hamilton, Mary R.
Other author	United States. General Accounting Office.
Format	Microform
Publication Info	Washington, D.C. : The Office ; Gaithersburg, MD (P.O. Box 6015, Gaithersburg 20884-6015) : The Office [distributor], [1996]
Description	13 pages, 2 unnumbered pages : illustrations ; 28 cm.
Subjects	United States. Food and Drug Administration. Drugs--United States. --Testing. Drugs--Law and legislation. --United States.

Series	Testimony ; GAO/T-PEMD-96-9 Testimony GAO/T-PEMD-96-9. ^A682308
General note	Distributed to depository libraries in microfiche.
General note	Shipping list no.: 98-0141-M.
General note	"May 2, 1996."
Bibliography note	Includes bibliographical references.
Reproduction note	Joyner- Microfiche. [Washington, D.C] : U.S. General Accounting Office, [1996] 1 microfiche : negative.
GPO item number	0546-D-01 (MF)
Govt. docs number	GA 1.5/2:T-PEMD-96-9

Availability

Library	Location	Call Number	Status	Item Actions
Joyner	Microforms B300	GA 1.5/2:T-PEMD-96-9	✔ Available

FDA review times : statement of Mary R. Hamilton, Director of Program Evaluation in Human Services Areas, Program Evaluation and Methodology Division, before the Subcommittee on Health and Environment, Committee on Commerce, House of Representatives / United States General Accounting Office.

Click here for more information about this title

Availability